- Home
- RDZN vs INO Comparison
RDZN vs INO Comparison
Compare RDZN & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDZN | INO |
|---|---|---|
| Founded | 2015 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.2M | 100.4M |
| IPO Year | 2021 | 1999 |
Fundamental Metrics
Financial Performance| Metric | RDZN | INO |
|---|---|---|
| Price | $1.40 | $0.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 247.2K | ★ 4.7M |
| Earning Date | 02-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.12 | 54.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $55,021,792.00 | $42,220,086.00 |
| Revenue This Year | $33.77 | $20,156.19 |
| Revenue Next Year | $51.46 | $421.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.21 | 19.37 |
| 52 Week Low | $0.81 | $0.56 |
| 52 Week High | $2.56 | $2.86 |
Technical Indicators
Market Signals| Indicator | RDZN | INO |
|---|---|---|
| Relative Strength Index (RSI) | 60.22 | 50.23 |
| Support Level | $1.38 | $0.56 |
| Resistance Level | $1.47 | $1.24 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 96.45 | 64.41 |
Price Performance
Historical ComparisonAbout RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express. Geographically, the company operates in India, United States of America, United Kingdom, and China. It generates maximum revenue form India.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.